Mangoceuticals Stock Surges 42% on TRT Sales Growth; CEO Highlights Telehealth Advantage
Mangoceuticals, a men's hormone health telehealth platform, saw its stock jump 42% amid acceleration in testosterone replacement therapy sales. CEO Jacob Cohen attributed gains to the company's telehealth advantage and reduced customer acquisition costs.
ED
Editor
5/5/20261 min read
Mangoceuticals stock surged 42.12% following strong TRT sales growth, signalling robust demand in the men's hormone health telehealth market. The rally reflects investor confidence in the company's direct-to-consumer model for testosterone therapy.
Mangoceuticals operates a telehealth platform focused on men's hormone health, delivering TRT and related therapies through licensed practitioners. The platform targets men seeking accessible, convenient hormone management without traditional clinic friction.
CEO Jacob Cohen highlighted two key drivers: the telehealth platform's inherent competitive advantage and a meaningful reduction in customer acquisition costs. Lower CAC suggests improving unit economics and potential for profitable scale.
The public market validation underscores persistent demand for men's health telehealth, particularly in hormone therapy where regulatory clarity has matured and consumer awareness has grown. The company's profitability signals are rare in early-stage health tech.